Sino Biopharm's benmelstobart shows promise in lung cancer treatment

Sino Biopharmaceutical Limited (HKEX: 1177) announced positive results from its Phase III clinical study of Benmelstobart Injection in combination with chemotherapy followed by sequential combination with Anlotinib for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the study demonstrated that the regimen significantly prolonged median progression-free survival (mPFS) to 10.12 months, representing a 36% reduction in the risk of disease progression compared to the control group. The objective remission rate (ORR) was 71.9% in the trial group versus 65.1% in the control group. The marketing application for the regimen has been accepted by the Centre for Drug Evaluation (CDE) of the National Medical Products Administration of the PRC in April. The study, involving 565 patients, is the world's first head-to-head Phase III clinical study of PD-1 monoclonal antibodies combined with chemotherapy for this indication.